Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And I should care because…
Odd. I actually thought these two id’s were from the same person. Conflicting internal voices?
NASDAQ, not acquisition was the wording used. Either would be welcome news.
“This is a Carter project, I definitely want us to go to a calendar year and he is resisting. So we'll figure it out. He seems to think we'll go to NASDAQ faster, but I'm working on him. It's the first thing I asked Carter to do when he joined the company…”
Part of the immediate growth need is due to Prasco. Highly correlated issue, but I see your point.
I think he was simply stating the trajectory and that we have a whole slew of good news coming in 2024, next year and beyond. Financials, pipeline expansion and movement to submissions, facility expansion, Prasco, etc. Lots of good news coming this year setting ourselves up to get more exposure.
Come now, did you actually spend $4,000+ to read the report?
There was similar one done years ago on Abuse deterrence R&D that showed Elite made the biggest investments among all competitors and yet SequestOx is where today?
Per last cc, we are filing final needle mover in 2024, which we presume to be Concerta at this point. He mentioned also that we plan to file a 2nd ANDA that sounds like it may have a large market as well. Do we have any insights regarding this one? Don’t think it’s methotrexeate.
Purdue/Knoa will become a not for profit. I have seen larger not for profits own for profit entities, but not sure I’d expect a relationship with Elite, but never know.
I’m banking on the same.
I don’t disagree, but with the time value of money over 10 year period…
Revenue in Q3 will include launch volume shipped before Jan 1. No one knows how much this will be. Perhaps it will be small and we’re overshooting. We’ll know soon enough in a couple week’s time and hoping to get a Prasco glimpse for going forward.
What Purdue did to push oxy is unbelievable with a total lack of integrity. There are many who need this drug and I think Elite will put the right processes and controls in place to market and distribute responsibly.
How could it be flat when you include Prasco launch quantity?
Agreed. Solid business growth coming this year. Hard part is we’ll have to wait until end of June for glimpse of full quarter for Prasco.
Everyone put your hands in the air for the coaster ride….
Couch said the same thing many years ago under $0.32…
But you have to pay the piper interest if you borrowed funds to invest.
How would that solve the share price requirement issue? Shell companies are usually acquired from privately held companies. Don’t think that makes any sense.
I was referring to portfolio balance amount.
I know. Schwab has been a painful transition. Scottrade was more powerful and user friendly way back in day.
Interesting. My Schwab portfolio doesn’t change regardless of pre/post market, only during reg session. I primarily use phone app.
I see bid at 0.197 again. Little volume traded per-market
Vigabatrin contract with Pyros is bringing in as much as Dexcel, Dr Reddy, etc. Lots of partnerships over years that haven’t brought in a dime.
Of course they waited until the last minute. Why would they submit it any day earlier? It doesn’t work to Upsher’s advantage. Drag this baby out as long as possible is the goal.
Sound off on Jerry’s dogs barking.
Dude, I put that one on mute long ago. The rare occasional good post wasn’t worth all the other garbage.
Easy on the language. Your annual review is coming up soon.
I used to buy on margin on a regular basis. Some stocks you can’t buy on margin as brokerage dictates that list. Brokerages want you to buy on margin as you are borrowing funds from them and pay an interest rate. Be sure to set up a margin account in advance if haven’t done so already. Can only do it in non-retirement accounts too.
At first I thought this was share count owned and almost soiled myself.
A doctor was held at gunpoint few years ago in upper Midwest over opioids. A close friend of mine was called in to help manage the situation. Needless to say the clinic was closed for a while and I believe the doctor retired. Very sad.
I believe there is still the stay in place that only permits the first generic approved filer to sell aside from the brand. I think floodgates open later this year to all others who have been approved.
Extremely conservative FY24 revenue that is excluding any approval from dopamine agonist and antimetabolite smaller drugs that we are expecting any day now. Also, you are basically excluding the Prasco deal, which will be significant. On top of that you assume generic Vyvanse won’t provide any incremental value this fiscal year. Throw on vigabatrin contract mfg too. I’ll buy in that generic oxy still has plenty of of hurdles, but not any of the others. I think we’ll see Q3 higher than this answer for certain our fiscal Q4.
Enjoy the ride.
500M day would be really nice. :)
A very small % of outstanding shares are sold daily. Even on a 500M day, that’s still one-half of 1%.
I think the 20’s were a great decade. So were the 90’s. Soon enough…
Perhaps it’s just me, but I do my best to avoid any bids in the ass. :)
I think it has more to do since Nov cc and new financial trajectory.
Bid is also at a dime, which we know isn’t real.